Tygacil Related Published Studies
Well-designed clinical trials related to Tygacil (Tigecycline)
Tigecycline for the treatment of severe Clostridium difficile infection. [2011.07]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. [2011.04]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam
in the treatment of complicated skin and skin structure infections in patients
from India and Taiwan. [2011]
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. [2010.12]
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. [2010.07.21]
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. [2010.04]
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. [2010.01.15]
Safety and efficacy of intravenous tigecycline in subjects with secondary
bacteremia: pooled results from 8 phase III clinical trials. [2010]
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. [2009.01]
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. [2008.10]
Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. [2008.10]
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. [2008.10]
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. [2008.09]
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. [2008.01]
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. [2007.06]
Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. [2007.04]
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. [2005.11]
A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. [2005.10.19]
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. [2005.09.01]
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. [2005.09]
Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. [2005.01]
Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. [2004.05]
Well-designed clinical trials possibly related to Tygacil (Tigecycline)
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. [2012]
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis,
treatment and resistance. [2012]
Other research related to Tygacil (Tigecycline)
Patients enrolled in randomised clinical trials are not representative of
critically ill patients in clinical practice: observational study focus on
tigecycline. [2013]
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage
tigecycline regimens versus imipenem-cilastatin for treatment of
hospital-acquired pneumonia. [2013]
Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline. [2011.12.05]
Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial, 2004-2009. [2011.11.19]
Susceptibility to Tigecycline and Linezolid Among Gram-Positive Isolates Collected in the United States as Part of the Tigecycline Evaluation and Surveillance Trial (TEST) Between 2004 and 2009. [2011.11.09]
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. [2011.11]
Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia. [2011.10.03]
Efficacy and safety of tigecycline: a systematic review and meta-analysis. [2011.09]
Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. [2011.07]
Local treatment of chronic osteomyelitis with surgical debridement and tigecycline-impregnated calcium hydroxyapatite: an experimental study. [2011.06.17]
In vitro activity of tigecycline against extended-spectrum beta-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study. [2011.06]
Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. [2011.06]
Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. [2011.04]
Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report. [2011.04]
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. [2011.03]
Tigecycline treatment of critically ill patients: the LatinUser experience. [2011.02]
Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. [2011.02]
Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. [2011]
Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. [2011]
Efficacy and safety of tigecycline for the treatment of infectious diseases: a
meta-analysis. [2011]
Efficacy and safety of tigecycline: a systematic review and meta-analysis. [2011]
Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. [2010.11.30]
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. [2010.10]
Factors associated with adherence to guidelines for the use of tigecycline in a tertiary care hospital. [2010.10]
[Tigecycline--a new antibiotic] [2010.08.26]
A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. [2010.08]
Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. [2010.08]
Failure of tigecycline to treat severe Clostridium difficile infection. [2010.07]
Superinfection during treatment of nosocomial infections with tigecycline. [2010.07]
S-thanatin enhances the efficacy of tigecycline in an experimental rat model of polymicrobial peritonitis. [2010.07]
Guideline: appropriate use of tigecycline. [2010.06.01]
Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. [2010.05]
Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. [2010.04]
Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. [2010.04]
Tigecycline in the treatment of ventilator-associated pneumonia: experience from the Latin American Tigecycline Use Registry. [2010.03]
Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. [2010.03]
Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. [2010.03]
Francis Tally and the discovery and development of tigecycline: a personal reminiscence. [2010.01.01]
Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia. [2010.01]
Tigecycline population pharmacokinetics in patients with community- or
hospital-acquired pneumonia. [2010]
A multicentre, open-label, randomized comparative study of tigecycline versus
ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects
with complicated intra-abdominal infections. [2010]
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese
patients with complicated intra-abdominal infections: a randomized controlled
trial. [2010]
In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. [2009.12]
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. [2009.09.09]
Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). [2009.08]
Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. [2009.07]
Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. [2009.07]
Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. [2009.07]
Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. [2009.07]
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. [2009.06.15]
[Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain] [2009.06]
Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. [2009.05]
Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. [2009.05]
Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. [2009.04]
Antimicrobial activity of tigecycline against nosocomial pathogens in Pakistan: a multicenter study. [2009.04]
Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. [2009.04]
[Tigecycline for treatment of pneumonia] [2009.02]
[Tigecycline: Its position between other antibiotics, features, clinical usage] [2009.02]
Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. [2009.02]
Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America. [2009.02]
Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. [2009.01]
Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. [2009.01]
Tigecycline. [2009.01]
A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). [2009]
A review of tigecycline--the first glycylcycline. [2008.12]
Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. [2008.11]
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. [2008.11]
Establishing the role of tigecycline in an era of antimicrobial resistance. [2008.10]
Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. [2008.10]
[Activity of tigecycline against pathogen bacteria isolated in respiratory infectious disease in Europe. TEST study 2004-2007.] [2008.09.29]
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. [2008.09]
Tigecycline pharmacokinetic/pharmacodynamic update. [2008.09]
Tigecycline for the treatment of Acinetobacter infections: a case series. [2008.09]
In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. [2008.09]
Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia. [2008.09]
Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. [2008.08.21]
Tigecycline: a new antibiotic. [2008.08]
|
